Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Neumora Therapeutics, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -16.7% on 2026-05-07
Conservative balance sheet (liabilities/equity 0.84x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Neumora Therapeutics, Inc. shows limited reported revenue, and -228.1% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001885522, latest 10-Q filed 2026-05-07) · EODHD · rules-based read · as of 6/17/2026, 7:45:18 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$136M | -$252M | -$263M | -$241M |
| Net income | -$131M | -$236M | -$244M | -$237M |
| Diluted EPS | -$4.81 | -$3.63 | -$1.53 | -$1.45 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2026-02-17 | Aurora Daljit Singh See Remarks | Sell | 6.17K @ $3.56 | $21.9K |
| 2026-02-17 | Pinto Joshua President | Sell | 5.97K @ $3.54 | $21.1K |
| 2026-02-17 | BERNS PAUL L See Remarks | Sell | 9.82K @ $3.51 | $34.5K |